Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form. E-metanicotine-type compounds that include a five-membered heteroaryl ring linked to an olefinic linker, such as a penten-2-amine linker, which is linked to a terminal amine group, are also disclosed. Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, can be treated by administering the compounds, pharmaceutical salts of the compounds, or pharmaceutical compositions including the compounds or their salts, to a patient in need thereof.
